Wide Ranks

BTAI

BioXcel Therapeutics, Inc.

0.4524

Top Statistics
Market Cap 21 M Forward PE -0.3335 Revenue Growth 141.60 %
Current Ratio 2.35 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.6570 Enterprise / Revenue 28.53 Price To Sales Trailing12 Months 9.10
Profitability
Profit Margins 0.00 % Operating Margins -1489.13 %
Balance Sheet
Total Cash 56 M Total Cash Per Share 1.38 Total Debt 103 M
Total Debt To Equity Current Ratio 2.35 Book Value Per Share -1.89
All Measures
Short Ratio 93.00 % Message Board Id finmb_543567629 Shares Short Prior Month 516384
City New Haven Uuid ed3396e0-a498-379a-b23a-cf6795d0f871 Previous Close 0.4638
First Trade Date Epoch Utc 1 B Book Value -1.89 Beta 0.2890
Total Debt 103 M Volume 736305 Fifty Two Week Low 0.4200
Total Cash Per Share 1.38 Total Revenue 2 M Shares Short Previous Month Date 1 B
Target Median Price 5.00 Audit Risk 8 Max Age 86400
Recommendation Mean 2.00 Sand P52 Week Change 0.3133 Operating Margins -1489.13 %
Target Mean Price 4.20 Net Income To Common -107832000 Short Percent Of Float 0.0109
Implied Shares Outstanding 48 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 656970 Average Volume10days 656970 Total Cash 56 M
Next Fiscal Year End 1 B Revenue Per Share 0.0740 Held Percent Insiders 0.2006
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 6 Regular Market Previous Close 0.4638 Target Low Price 1.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.5891 Open 0.4640
Free Cashflow -65595124 State CT Dividend Yield 0.00 %
Return On Assets -0.6362 Time Zone Short Name EST Board Risk 8
Trailing Eps -2.04 Day Low 0.4202 Address1 555 Long Wharf Drive
Shares Outstanding 48 M Compensation Risk 10 Price Hint 4
Target High Price 7.00 Website https://www.bioxceltherapeutics.com 52 Week Change -0.8811
Average Volume 524626 Forward Eps -1.66 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 209.20 % Is_sp_500 False
Regular Market Day High 0.4699 Profit Margins 0.00 % Fifty Two Week High 4.17
Day High 0.4699 Shares Short 347081 Regular Market Open 0.4640
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 28.53
Revenue Growth 141.60 % Shares Percent Shares Out 0.0085 Operating Cashflow -105327000
Currency USD Time Zone Full Name America/New_York Market Cap 21 M
Is_nasdaq_100 False Zip 06511 Quote Type EQUITY
Industry Biotechnology Long Name BioXcel Therapeutics, Inc. Overall Risk 9
Regular Market Day Low 0.4202 Held Percent Institutions 0.0876 Current Price 0.4524
Address2 12th Floor Enterprise To Ebitda -0.6570 Financial Currency USD
Current Ratio 2.35 Gross Margins 43.11 % Industry Disp Biotechnology
Number Of Analyst Opinions 5 Country United States Float Shares 29 M
Two Hundred Day Average 1.52 Governance Epoch Date 1 B Enterprise Value 68 M
Price To Sales Trailing12 Months 9.10 Forward PE -0.3335 Regular Market Volume 736305
Ebitda -104299000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.

The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.

Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia.

In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia.

BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.